No Data
FOSUN INTL: ANNUAL REPORT 2024
Nanyang Commercial Bank Enters Into Strategic Cooperation Agreement With Fosun International
[Brokerage Focus] Guozheng International maintains a Buy rating on FOSUN INTL (00656) indicating that the impact of one-time asset disposal gains and losses as well as changes in the macroeconomic environment on its performance is significant.
Golden Owl Financial News | National Securities International Research indicates that FOSUN INTL (00656) achieved revenue of 192.1 billion yuan, a year-on-year decrease of 3.1%; it reported a Net income of -4.35 billion yuan, mainly due to the impairment provision of 5.1 billion for the Cainiao project. Excluding this part, the Net income attributable to the parent company is 0.75 billion yuan. The firm states that in 2024, the revenue of the health Sector will be 46.5 billion, a year-on-year increase of 0.5%, with a Net income of 0.9 billion, up 55% year-on-year. This is mainly due to the increase in profit attributable to the Shareholder of FOSUN PHARMA compared to the same period last year, and the good performance of investment projects in the health Sector; in 2024, the revenue of the happiness Sector is 76.7 billion, year-on-year decline.
FOSUN INTL (00656) increased its Shareholding in HENLIUS (02696) by a total of 3.87%.
FOSUN INTL (00656) announced that on April 17, 2025, FOSUN PHARMA industry (the company through FOSUN...
Express News | Fosun International - Henlink Agreed to Sell 14.9 Mln Unlisted Shares of Henlius to Fosun Pharma Industrial at HKD24.6 per Share
Express News | Fosun International - Total Consideration Is HKD367.5 Mln
